Diagnosis and management of pigmentary glaucoma

Current Opinion in Ophthalmology

Volumn 9, Issue 2, 1998, Pages 61-64

  Lehto, Ilkka ^a   Vesti, Eija ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; DAPIPRAZOLE;

GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; IRIDOTOMY; LASER SURGERY; MYOPIA; PIGMENTATION; PRIORITY JOURNAL; REVIEW; TRABECULAR MESHWORK;

EID: 0031747681     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199804000-00012     Document Type: Review

References (13)

1. Ritch R: A unification hypothesis of pigment dispersion syndrome. Trans Am Ophthatmol Soc 1996, 94:381-409. Reviews and analyzes the literature on pigment dispersion syndrome (PDS) and tries to arrive at a hypothesis concerning the nature of an underlying genetic predisposition.
2. Pavlin CJ, Macken P, Trope GE, Harasiewicz K, Foster FS: Accommodation and iridotomy in the pigment dispersion syndrome. Ophthalmic Surg Lasers 1996, 27:113-120.
3. Sokol J, Stegman Z, Liebmann JM, Ritch R: Location of the iris insertion in pigment dispersion syndrome. Ophthalmology 1996, 103:289-293.
4. Mastropasqua L, Ciancaglini M, Carpineto P, Gallenga PE: Early stadiation of pigmentary dispersion syndrome and long term analysis of progression to pigmentary glaucoma. Ann Ophthalmol Glaucoma 1996, 28:301-307.
5. Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE: The effectiveness of dapiprazole in preventing exercise-induced IOP increase in patients with pigmentary dispersion syndrome. Int Ophthalmol 1996, 19:359-362.
6. Mastropasqua L, Carpineto P, Ciancaglini M, Lobefalo L, Costagliola C, Gallenga PE: Effect of dapiprazole, an alpha-adrenergic blocking agent, on aqueous humor dynamics in pigmentary glaucoma. Ophthalmic Res 1996, 28:312-318. Dapiprazole causes miosis without accommodation spasms or vitreoretinal traction. Its effect in lowering the intraocular pressure (IOP) in eyes with pigmentary glaucoma (PG) treated with timolol 0.5% is documented.
7. Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE: The usefulness of dapiprazole, an alpha-adrenergic blocking agent, in pigmentary glaucoma. Ophthalmic Surg Lasers 1996, 27:806-809.
8. Camras CB, Alm A, Watson P, Stjernschantz J, the Latanoprost Study Groups: Latanoprost a prostaglandin analog, for glaucoma therapy: efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 1996, 103:1916-1924
9. Jacobi PC, Krieglstem GK: Trabecular aspiration: a new mode to treat pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci 1995, 36:2270-2276.
10. Gandolfi SA, Vecchi M: Effect of a YAG laser iridotomy on intraocular pressure in pigment dispersion syndrome. Ophthalmology 1996, 103:1693-1695.
11. Wollensak G, Eberwein P, Funk J: Perforation rosette of the lens after Nd:YAG laser iridotomy. Am J Ophthalmol 1997, 123:555-557.
12. Scuderi G, Papale A, Nucci C, Cerulli L: Retinal involvement in pigment dispersion syndrome. Int Ophthalmol 1996, 19:375-378. The high percentage of lattice degenerations found in eyes with PDS stresses the importance of retinal examination to detect degenerations needing treatment.
13. Andersen JS, Pralea AM, DelBono EA, Haines JL, Gonn MB, Schuman JS. Mattox CG, Wiggs JL: A gene responsible for the pigment dispersion syndrome maps to chromosome 7q35-q36. Arch Ophthalmol 1997, 115:384-388.